Evotec 566480, wohin geht die Reise??? (Seite 5667)
eröffnet am 12.01.07 11:23:52 von
neuester Beitrag 19.04.24 18:00:01 von
neuester Beitrag 19.04.24 18:00:01 von
Beiträge: 81.629
ID: 1.104.790
ID: 1.104.790
Aufrufe heute: 3.196
Gesamt: 16.120.503
Gesamt: 16.120.503
Aktive User: 0
ISIN: DE0005664809 · WKN: 566480
13,230
EUR
-0,71 %
-0,095 EUR
Letzter Kurs 23:00:15 Lang & Schwarz
Neuigkeiten
| Evotec Aktien ab 5,80 Euro handeln - Ohne versteckte Kosten!Anzeige |
19:00 Uhr · Felix Haupt Anzeige |
18.04.24 · Shareribs Anzeige |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3.000,00 | +74.900,00 | |
| 2,4700 | +33,51 | |
| 1,1060 | +30,10 | |
| 1,5400 | +25,71 | |
| 12,400 | +23,26 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,0400 | -15,00 | |
| 1,7000 | -15,00 | |
| 0,7350 | -15,03 | |
| 4,6600 | -28,75 | |
| 0,6021 | -35,26 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 46.887.732 von Radiesel2008 am 28.04.14 18:12:38... nein,- die sind alle zu epi abgewandert.
dort trifft sich das top der trader wieder.....was man da für Namen wieder findet.....
dort trifft sich das top der trader wieder.....was man da für Namen wieder findet.....
Allerdings muss ich anmerken, dass schon eine gewisse Wahrscheinlichkeit besteht, dass es passieren kann. Ukraine Krise, Sommerloch, etc.pp. Ist halt gerade eine blöde Zeit... Aber das hat sicher nix mit der ANALyse von AC zu tun...
Antwort auf Beitrag Nr.: 46.887.290 von submersus am 28.04.14 17:15:38Also was Aktienschreck verzapft lese ich schon lange nicht mehr. Die haben 50% Trefferquote... (im besten Fall). Da kann man auch eine Münze werfen...
Irgendwas stimmt hier aber wirklich nicht, erneut auf Tagestief! Und das nach den ach so super Nachrichten mit dem Meilensteinchen....
Antwort auf Beitrag Nr.: 46.887.258 von Radiesel2008 am 28.04.14 17:10:25Moin,
Die schreiben sich ein Dreck herbei..." target="_blank" rel="nofollow ugc noopener">http://www.aktiencheck.de/exklusiv/Artikel-Evotec_Aktie_Vorsicht_Dammbruch_Finger_weg_Chartanalyse-5666396....
Die schreiben sich ein Dreck herbei..." target="_blank" rel="nofollow ugc noopener">http://www.aktiencheck.de/exklusiv/Artikel-Evotec_Aktie_Vorsicht_Dammbruch_Finger_weg_Chartanalyse-5666396....
Trading Spotlight
Antwort auf Beitrag Nr.: 46.887.182 von depulep am 28.04.14 16:58:10Was lässt Dich eigentlich so einen Käse zu verzapfen? Kannst Du mal Deinen Quatsch kommentieren/belegen? Wo shorted Aktiencheck Evotec?
Dann steht laut Deiner Aussage ein "Dammbruch" bevor und Du bist reingegangen... Da kann ja nicht mal mehr der Arzt helfen...
Dann steht laut Deiner Aussage ein "Dammbruch" bevor und Du bist reingegangen... Da kann ja nicht mal mehr der Arzt helfen...
die herren von aktiencheck schorten die aktie
ihr dürft da jah nich reingehn
dammbruch steht bevor da weis man doch was abgeht
ichbin reingegangen und bleib dabei.
ihr dürft da jah nich reingehn
dammbruch steht bevor da weis man doch was abgeht
ichbin reingegangen und bleib dabei.
------------------------
ukraine steht noch
russland is zu hause geblieben
evotec wird weiter gedeckelt
kaum handel
kurs langsam nach unten
gute nachrichten werden nicht wahrgenommen
armes evotec
russland is zu hause geblieben
evotec wird weiter gedeckelt
kaum handel
kurs langsam nach unten
gute nachrichten werden nicht wahrgenommen
armes evotec
PR Newswire
OXFORD England April 28 2014
OXFORD England April 28 2014 /PRNewswire-USNewswire/ -- Orca Pharmaceuticals a biotechnology start-up developing RORgamma inhibitors for the treatment of autoimmune diseases has announced a further investment of $1.3 million from BioMotiv a drug development accelerator based in Cleveland Ohio and affiliated with The Harrington Project.Founded in 2013 the company's technology is based on intellectual property developed in the laboratory of Professor Dan Littman of New York University a world leader in Th17 cell immunology.Orca also has close ties with Oxford University immunologists who are playing a key role in identifying promising therapeutic indications and selecting an optimised development candidate.
"This additional funding endorses the strength of the Orca program and provides resources for the advancement of a development candidate" said Roy Pettipher PhD founder and Chief Scientific Officer of Orca Pharmaceuticals.
Orca Pharmaceuticals is developing an oral drug to treat a range of autoimmune diseases with psoriasis as the primary therapeutic target. Working with Evotec AG the company has developed a series of potent and selective compounds with pharmaceutical properties that are amenable to clinical development. The additional investment will enable the company to select a clinical candidate optimised for activity on key pathogenic immune cells.
"The powerful combination of high quality medicinal chemistry target structure analysis and leading edge biological screening has enabled Orca to obtain potentially best-in-class RORgamma inhibitors targeting a variety of immune diseases" said David C. U'Prichard PhD Board Chairman of Orca Pharmaceuticals and Chief Scientific Officer of BioMotiv.
Mick Hunter PhD CEO of Orca Pharmaceuticals indicated that the company is now exploring additional development partnerships with pharmaceutical companies.
ContactOrca Pharmaceuticals LtdRoy Pettipher+44 (0) 1235 841542 rpettipher@orcaph.com
About Orca Pharmaceuticals
Orca Pharmaceuticals is a biopharmaceutical company focused on the discovery development and commercialization via partnership of targeted small molecule RORgamma inhibitor drugs to treat patients with autoimmune disease.For more information please visit: http://www.orcapharmaceuticals.com
About BioMotiv
BioMotiv is the mission-driven accelerator associated with The Harrington Project for Discovery & Development a $250 million national initiative for advancing medicine centered at University Hospitals of Cleveland.The focus is to accelerate breakthrough discoveries from research institutions into therapeutics for patients through an innovative model that efficiently aligns capital and collaborations.The company leverages an experienced team and advisory board to select fund and actively manage and advance a portfolio of programs.Products are advanced to clinical proof-of-concept and then partnered. Bio
More: http://www.pharmiweb.com/PressReleases/pressrel.asp?ROW_ID=8…
OXFORD England April 28 2014
OXFORD England April 28 2014 /PRNewswire-USNewswire/ -- Orca Pharmaceuticals a biotechnology start-up developing RORgamma inhibitors for the treatment of autoimmune diseases has announced a further investment of $1.3 million from BioMotiv a drug development accelerator based in Cleveland Ohio and affiliated with The Harrington Project.Founded in 2013 the company's technology is based on intellectual property developed in the laboratory of Professor Dan Littman of New York University a world leader in Th17 cell immunology.Orca also has close ties with Oxford University immunologists who are playing a key role in identifying promising therapeutic indications and selecting an optimised development candidate.
"This additional funding endorses the strength of the Orca program and provides resources for the advancement of a development candidate" said Roy Pettipher PhD founder and Chief Scientific Officer of Orca Pharmaceuticals.
Orca Pharmaceuticals is developing an oral drug to treat a range of autoimmune diseases with psoriasis as the primary therapeutic target. Working with Evotec AG the company has developed a series of potent and selective compounds with pharmaceutical properties that are amenable to clinical development. The additional investment will enable the company to select a clinical candidate optimised for activity on key pathogenic immune cells.
"The powerful combination of high quality medicinal chemistry target structure analysis and leading edge biological screening has enabled Orca to obtain potentially best-in-class RORgamma inhibitors targeting a variety of immune diseases" said David C. U'Prichard PhD Board Chairman of Orca Pharmaceuticals and Chief Scientific Officer of BioMotiv.
Mick Hunter PhD CEO of Orca Pharmaceuticals indicated that the company is now exploring additional development partnerships with pharmaceutical companies.
ContactOrca Pharmaceuticals LtdRoy Pettipher+44 (0) 1235 841542 rpettipher@orcaph.com
About Orca Pharmaceuticals
Orca Pharmaceuticals is a biopharmaceutical company focused on the discovery development and commercialization via partnership of targeted small molecule RORgamma inhibitor drugs to treat patients with autoimmune disease.For more information please visit: http://www.orcapharmaceuticals.com
About BioMotiv
BioMotiv is the mission-driven accelerator associated with The Harrington Project for Discovery & Development a $250 million national initiative for advancing medicine centered at University Hospitals of Cleveland.The focus is to accelerate breakthrough discoveries from research institutions into therapeutics for patients through an innovative model that efficiently aligns capital and collaborations.The company leverages an experienced team and advisory board to select fund and actively manage and advance a portfolio of programs.Products are advanced to clinical proof-of-concept and then partnered. Bio
More: http://www.pharmiweb.com/PressReleases/pressrel.asp?ROW_ID=8…
Durchsuchen
18.04.24 · wO Newsflash · American Express |
18.04.24 · wO Newsflash · Evotec |
18.04.24 · EQS Group AG · Evotec |
18.04.24 · Sharedeals · Evotec |
| Zeit | Titel |
|---|---|
| 18.04.24 | |
| 13.02.24 | |
| 22.01.24 | |
| 17.01.24 | |
| 08.01.24 | |
| 15.05.23 |